He pointed out that the vaccine called "EpiVacCorona" will have an initial production of 60,000 doses, which would be supplied to 40,000 volunteers during clinical trials.
On Sept. 30, the Vektor Center concluded phases 1 and 2 of the EpiVacCorona clinical trials and demonstrated that this antiviral is safe for delivery to humans.
The EpiVacCorona vaccine is a synthetic preparation and this differentiates it from the first Russian registered vaccine, the Sputnik V, which is based on a "cold" version of the new coronavirus and was developed by the Gamaleya Research Center.
The United States has passed 7.8 million confirmed cases, with over 215,000 deaths from COVID-19, the highest numbers in the world. Over 3.1 million Americans have been deemed recovered, according to data compiled from various sources by Johns Hopkins University pic.twitter.com/CScuC4PQjG